Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2015

Open Access 01-12-2015 | Study protocol

Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial

Authors: Maarten Cuypers, Romy E. D. Lamers, Paul J. M. Kil, Lonneke V. van de Poll-Franse, Marieke de Vries

Published in: Trials | Issue 1/2015

Login to get access

Abstract

Background

At an early stage, prostate cancer patients are often eligible for more than one treatment option, or may choose to defer curative treatment. Without a pre-existing superior option, a patient has to weigh his personal preferences against the risks and benefits of each alternative to select the most appropriate treatment. Given this context, in prostate cancer treatment decision-making, it is particularly suitable to follow the principles of shared decision-making (SDM), especially with the support of specific instruments like decision aids (DAs). Although several alternatives are available, present tools are not sufficiently compatible with routine clinical practice. To overcome existing barriers and to stimulate structural implementation of DAs and SDM in clinical practice, a web-based prostate cancer treatment DA was developed to fit clinical workflow. Following the structure of an existing DA, Dutch content was developed, and values clarification methods (VCMs) were added. The aim of this study is to investigate the effect of this DA on (shared) treatment choice and patient-reported outcomes.

Methods/design

Nineteen Dutch hospitals are included in a pragmatic, cluster randomized controlled trial, with an intervention and a control arm. In the intervention group, the DA will be offered after diagnosis, and a summary of the patients’ preferences, which were identified with the DA, can be discussed by the patient and his clinician during later consultation. Patients in the control group will receive information and decisional support as usual. Results from both groups on decisional conflict, treatment choice and the experience with involvement in the decision-making process are compared. Patients are requested to fill in questionnaires after treatment decision-making but before treatment is started, and 6 and 12 months later. This will allow the development of treatment satisfaction, decisional regret, and quality of life to be monitored. Clinicians from both groups will evaluate their practice of information provision and decisional support.

Discussion

This study will describe a web-based prostate cancer treatment DA with VCMs. The effect of this DA on the decision-making process and subsequent patient reported outcomes will be evaluated.

Trial registration

The Netherlands National Trial Register: NTR4554, registration date 1 May 2014.
Literature
1.
2.
Post P, Kil P, Crommelin M, Schapers R, Coebergh J-W. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971–1995. Eur J Cancer. 1998;34:705–9.CrossRefPubMed
3.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–90.CrossRefPubMed
4.
Dutch Cancer Society. Kwaliteit van kankerzorg in Nederland: voortgang en blik op de toekomst. Amsterdam: KWF Kankerbestrijding; 2014.
5.
6.
Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100:544–51.CrossRefPubMed
7.
Van den Bergh RC, Korfage IJ, Bangma CH. Psychological aspects of active surveillance. Curr Opin Urol. 2012;22:237–42.CrossRefPubMed
8.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. 2014;65:124–37.CrossRefPubMed
9.
Kramer KM, Bennett CL, Pickard AS, Lyonsn EA, Wolf MS, McKoy JM, et al. Patient preferences in prostate cancer: a clinician’s guide to understanding health utilities. Clin Prostate Cancer. 2005;4:15–23.CrossRefPubMed
10.
Song L, Chen RC, Bensen JT, Knafl GJ, Nielsen ME, Farnan L, et al. Who makes the decision regarding the treatment of clinically localized prostate cancer–the patient or physician? Cancer. 2013;119:421–8.CrossRefPubMed
11.
12.
Hoffmann TC, Légaré F, Simmons MB, McNamara K, McCaffery K, Trevena LJ, et al. Shared decision making: What do clinicians need to know and why should they bother? Med J Aust. 2014;201:35–9.CrossRefPubMed
13.
Degner LF, Davison BJ, Sloan JA, Mueller B. Development of a scale to measure information needs in cancer care. J Nurs Meas. 1998;6:137–53.PubMed
14.
Sonn GA, Sadetsky N, Presti JC, Litwin MS. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol. 2013;189:S59–65.CrossRefPubMed
15.
Carlson LE, Waller A, Mitchell AJ. Screening for distress and unmet needs in patients with cancer: review and recommendations. J Clin Oncol. 2012;30:1160–77.CrossRefPubMed
16.
O’Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff. 2004;2004:63–72.
17.
18.
Vektis. Rapportage indicatoren indicatiestelling (praktijkvariatie). Zeist: Vektis; 2011.
19.
Comprehensive Cancer Center South. Factsheet prostate cancer. Eindhoven: IKZ; 2012.
20.
Healthcare Insurance Board. Robotprostaatchirurgie: Vanzelfsprekend? Diemen: CVZ; 2011.
21.
Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59:379–90. doi:10.3322/caac.20039.CrossRefPubMed
22.
Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin. 2015;65(3):239–51.CrossRefPubMed
23.
Feldman-Stewart D, Capirci C, Brennenstuhl S, Tong C, Abacioglu U, Gawkowska-Suwinska M, et al. Information for decision making by patients with early-stage prostate cancer a comparison across 9 countries. Med Decis Making. 2011;31:754–66.CrossRefPubMed
24.
Feldman-Stewart D, Tong C, Siemens R, Alibhai S, Pickles T, Robinson J, et al. The impact of explicit values clarification exercises in a patient decision Aid emerges after the decision is actually made evidence from a randomized controlled trial. Med Decis Making. 2012;32:616–26.CrossRefPubMed
25.
Elwyn G, O’Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aid: online international Delphi consensus process. BMJ. 2006;333:417–9.CrossRefPubMedPubMedCentral
26.
Eldridge S, Ashby D, Bennett C, Wakelin M, Feder G. Internal and external validity of cluster randomised trials: systematic review of recent trials. BMJ. 2008;336:876–80.CrossRefPubMedPubMedCentral
27.
Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:1–8.CrossRef
28.
29.
Schellings R, Kessels A, Sturmans F. Prerandomisatie bij wetenschappelijk onderzoek: een taboe doorbroken. Ned Tijdschr Geneeskd. 2008;152:2053–6.PubMed
30.
Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57:315–21.CrossRefPubMed
31.
Van de Poll-Franse LV, Horevoorts N, Eenbergen MV, Denollet J, Roukema JA, Aaronson NK, et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47:2188–94.CrossRefPubMed
32.
33.
Koedoot N, Molenaar S, Oosterveld P, Bakker P, de Graeff A, Nooy M, et al. The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns. 2001;45:187–93.CrossRefPubMed
34.
Feldman-Stewart D, Brundage M, Siemens R, Skarasgard D. A randomized controlled trial comparing two educational booklets on prostate cancer. Can J Urol. 2006;13:3321.PubMed
35.
Berry DL, Halpenny B, Hong F, Wolpin S, Lober WB, Russell KJ, et al. The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial. Urol Oncol. 2013;31:1012–21.CrossRefPubMed
36.
Hacking B, Wallace L, Scott S, Kosmala‐Anderson J, Belkora J, McNeill A. Testing the feasibility, acceptability and effectiveness of a ‘decision navigation’ intervention for early stage prostate cancer patients in Scotland–a randomised controlled trial. Psychooncology. 2013;22:1017–24.CrossRefPubMed
37.
Brehaut JC, O’Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Making. 2003;23:281–92.CrossRefPubMed
38.
Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med. 1996;156:1414–20.CrossRefPubMed
39.
Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O’Connor AM. Validation of a preparation for decision making scale. Patient Educ Couns. 2010;78:130–3.CrossRefPubMed
40.
Llewellyn CD, Horne R, McGurk M, Weinman J. Development and preliminary validation of a new measure to assess satisfaction with information among head and neck cancer patients: the satisfaction with cancer information profile (SCIP). Head Neck. 2006;28:540–8.CrossRefPubMed
41.
42.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
43.
Van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.CrossRefPubMed
44.
Uebersax JS, Wyman JF, Shumaker SA, McClish DK. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Neurourol Urodyn. 1995;14:131–9.CrossRefPubMed
45.
Moore KN, Jensen L. Testing of the incontinence impact questionnaire (IIQ‐7) with men after radical prostatectomy. Wound Ostomy Continence Nurs. 2000;27:304–12.
46.
Bloem S, Stalpers J. Subjective Experienced Health as a Driver of Health Care Behavior. Nyenrode Research Paper Series. 2012;12:1–19.
47.
Stacey D, Légaré F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:1–265.
48.
49.
Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;36:588–94.PubMed
50.
51.
Orom H, Penner LA, West BT, Downs TM, Rayford W, Underwood W. Personality predicts prostate cancer treatment decision‐making difficulty and satisfaction. Psychooncology. 2009;18:290–9.CrossRefPubMed
52.
Wong F, Stewart DE, Dancey J, Meana M, McAndrews MP, Bunston T, et al. Men with prostate cancer: influence of psychological factors on informational needs and decision making. J Psychosom Res. 2000;49:13–9.CrossRefPubMed
53.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
54.
Roth A, Nelson CJ, Rosenfeld B, Warshowski A, O’shea N, Scher H, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC). Psychosomatics. 2006;47:340–7.CrossRefPubMed
55.
Van den Bergh RC, Korfage IJ, Borsboom GJ, Steyerberg EW, Essink-Bot M-L. Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer. Qual Life Res. 2009;18:1061–6.CrossRefPubMedPubMedCentral
56.
Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol. 1994;67:1063.CrossRefPubMed
57.
Rammstedt B, John OP. Measuring personality in one minute or less: a 10-item short version of the Big Five Inventory in English and German. J Res Pers. 2007;41:203–12.CrossRef
58.
Ende J, Kazis L, Ash A, Moskowitz MA. Measuring patients’ desire for autonomy. J Gen Intern Med. 1989;4:23–30.CrossRefPubMed
59.
Schwartz B, Ward A, Monterosso J, Lyubomirsky S, White K, Lehman DR. Maximizing versus satisficing: happiness is a matter of choice. J Pers Soc Psychol. 2002;83:1178.CrossRefPubMed
60.
Fleuren MA, Paulussen TG, Van Dommelen P, Van Buuren S. Towards a measurement instrument for determinants of innovations. Int J Qual Health Care. 2014;26:501–10.CrossRefPubMedPubMedCentral
61.
Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol. 1994;47:787–95.CrossRefPubMed
62.
Campbell MK, Fayers PM, Grimshaw JM. Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clin Trials. 2005;2:99–107.CrossRefPubMed
63.
Bell ML, McKenzie JE. Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures. Psychooncology. 2013;22:1738–47.CrossRefPubMed
64.
Schofield P, Lofti-Jam K, Gough K, Dudgeon P, Bergin R, Crellin W, et al. A nurse-led group consultation intervention to reduce psychological morbidity and unmet needs in men with prostate cancer during radiotherapy: a randomised controlled trial. New York City, USA: MASCC/ISOO International Symposium on Supportive Care in Cancer; 2012. p. 145.
65.
Husson O, Thong MS, Mols F, Smilde TJ, Creemers G-J, van de Poll-Franse LV. Information provision and patient reported outcomes in patients with metastasized colorectal cancer: results from the PROFILES registry. J Palliat Med. 2013;16:281–8.CrossRefPubMedPubMedCentral
66.
Husson O, Mols F, Oranje W, Haak H, Nieuwlaat W, Netea‐Maier R, et al. Unmet information needs and impact of cancer in (long‐term) thyroid cancer survivors: results of the PROFILES registry. Psychooncology. 2014;23:946–52.CrossRefPubMed
67.
Murray DM, Pals SL, Blitstein JL, Alfano CM, Lehman J. Design and analysis of group-randomized trials in cancer: a review of current practices. J Natl Cancer Inst. 2008;100:483–91. doi:10.1093/jnci/djn066.CrossRefPubMed
68.
Nelson WL, Han PKJ, Fagerlin A, Stefanek M, Ubel PA. Rethinking the objectives of decision aids: a call for conceptual clarity. Med Decis Making. 2007;27:609–18. doi:10.1177/0272989x07306780.CrossRefPubMed
Metadata
Title
Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial
Authors
Maarten Cuypers
Romy E. D. Lamers
Paul J. M. Kil
Lonneke V. van de Poll-Franse
Marieke de Vries
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Trials / Issue 1/2015
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-015-0750-x

Other articles of this Issue 1/2015

Trials 1/2015 Go to the issue

Study protocol

Neurofeedback as a nonpharmacological treatment for adults with attention-deficit/hyperactivity disorder (ADHD): study protocol for a randomized controlled trial

Study protocol

The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial

Study protocol

Combining cognitive bias modification training with motivational support in alcohol dependent outpatients: study protocol for a randomised controlled trial

Study protocol

PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial

Study protocol

Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial

Study protocol

Extended brief intervention to address alcohol misuse in people with mild to moderate intellectual disabilities living in the community (EBI-ID): study protocol for a randomised controlled trial